Overview

Simvastatin in Waldenstrom's Macroglobulinemia

Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This research study seeks to find new ways to treat people with Waldenstrom's Macroglobulinemia (WM). The study is for participants with slow growing WM who otherwise might not need therapy for at least 3-6 months. Simvastatin is a drug approved by the FDA for lowering cholesterol. In test tube studies the study drug appears to have direct anti-cancer effect against WM tumor cells and mast cells.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Treatments:
Simvastatin